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Abstract
Background: Differentiating mild cognitive impairment (MCI) from dementia is important, as treatment options differ.
There are few short (<5 min) but accurate screening tools that discriminate between MCI, normal cognition (NC) and
dementia, in the Dutch language. The Quick Mild Cognitive Impairment (Qmci) screen is sensitive and specific in
differentiating MCI from NC and mild dementia. Given this, we adapted the Qmci for use in Dutch-language countries
and validated the Dutch version, the Qmci-D, against the Dutch translation of the Standardised Mini-Mental State
Examination (SMMSE-D).
Method: The Qmci was translated into Dutch with a combined qualitative and quantitative approach. In all, 90
participants were recruited from a hospital geriatric clinic (25 with dementia, 30 with MCI, 35 with NC). The Qmci-D and
SMMSE-D were administered sequentially but randomly by the same trained rater, blind to the diagnosis.
Results: The Qmci-D was more sensitive than the SMMSE-D in discriminating MCI from dementia, with a significant
difference in the area under the curve (AUC), 0.73 compared to 0.60 (p = 0.024), respectively, and in discriminating
dementia from NC, with an AUC of 0.95 compared to 0.89 (p = 0.006). Both screening instruments discriminated MCI
from NC with an AUC of 0.86 (Qmci-D) and 0.84 (SMMSE-D).
Conclusion: The Qmci-D shows similar,(good) accuracy as the SMMSE-D in separating NC from MCI; greater,(albeit fair),
accuracy differentiating MCI from dementia, and significantly greater accuracy in separating dementia from NC. Given
its brevity and ease of administration, the Qmci-D seems a useful cognitive screen in a Dutch population. Further study
with a suitably powered sample against more sensitive screens is now required.
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Background
The prevalence of mild cognitive impairment (MCI) [1]
and dementia [2] is increasing worldwide. Differentiating
MCI from dementia is important, because treatment
options differ. In particular, pharmaceutical therapy, in-
dicated for treatment of dementia, is inappropriate and
potentially even harmful, in those with MCI [3]. Differ-
entiating MCI from normal cognition (NC) is also im-
portant, because people with MCI are at increased risk
of developing dementia, compared to aged-matched
individuals in the population [4], and early identification
may allow prompt intervention [5, 6]. Few short
(administration time of approximately 5 min) cognitive
screening instruments are useful in discriminating be-
tween MCI and NC or dementia. Most are limited by
their sensitivity and specificity [7]. Likewise, few are
available in the Dutch language. One of the most widely
used tools is the Mini-Mental State Examination
(MMSE) [8]. The MMSE was standardized to improve
reliability, producing the Standardised Mini-Mental State
Examination (SMMSE) [9, 10], which is available in a
wide variety of languages including Dutch [11]. However,
there is limited evidence that either the MMSE or
SMMSE are sufficiently accurate in identifying MCI
[12], particularly in those with high educational attain-
ment [13].
To address these challenges, the Quick Mild Cognitive
Impairment (Qmci) screen was developed. Based upon
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the ABCS 135 [14], it was modified to increase its sensi-
tivity to differentiate NC from MCI, by the addition of
logical memory. The Qmci is more sensitive in differ-
entiating MCI from NC than the SMMSE and ABCS
135 [15]. The Qmci has six subtests, orientation,
registration, clock drawing, delayed recall, verbal flu-
ency and logical memory. It is scored out of
100 points, can be administered and scored in less
than 5 min and has excellent test-retest reliability
[16]. The Qmci correlates highly with the Standar-
dised ADAS-cog, Clinical Dementia Rating scale and
the Lawton-Brody activities of daily living scale [17].
The goal of the present study was to adapt the Qmci
for use in Dutch-language countries, to validate the
Dutch version of the Qmci (Qmci-D) and to compare its
sensitivity and specificity in differentiating MCI from
NC and dementia to the most widely used short cogni-
tive screen in the Netherlands, the Dutch version of the
SMMSE (SMMSE-D).
Methods
Translation
The translation of the Qmci was performed with a
combined qualitative and quantitative approach [18].
The original version of the Qmci was translated to
Dutch by a health professional with a good under-
standing of English, whose primary language is Dutch.
This Dutch version was reviewed by an expert panel
of Dutch health professionals and researchers and a
completed version of the Qmci-D was generated. A
professional, native English language-speaking transla-
tor, without knowledge of the concepts behind the
screening tool, performed the back-translation. The
back-translation was then reviewed by the original de-
velopers of the Qmci screen, who approved the final
version. The Qmci-D was pre-tested on participants
with normal cognition before it was used in this
study.
Participants
Consecutive patients were recruited during a four month-
period, between November 2013 and March 2014, from a
geriatric outpatient department in a regional hospital, in
the North of the Netherlands, where they were referred for
the assessment of cognitive problems. Normal controls
were recruited by convenience sampling among healthy
participants without cognitive problems, who were accom-
panying the patients. A diagnosis of dementia (Alzheimer’s
disease, vascular or mixed dementia subtypes) was made
using DSM-IV [19] and NINCDS-ADRDA [20] criteria. A
diagnosis of amnestic type MCI was made in patients
with objective memory loss, greater than expected with
ageing but without loss of social or occupational
function, according to the National Institute on
Aging- Alzheimer’s Association workgroups diagnostic
guidelines for Alzheimer’s disease [21]. Participants
were excluded if they were younger than 55, if they
had active depression (Geriatric Depression Scale >5),
if they weren’t able to communicate in Dutch or if
they were diagnosed with other MCI or dementia
subtypes, including frontotemporal dementia, Parkin-
son’s disease or Lewy Body dementia. Those with
frontotemporal, Parkinson’s disease and Lewy body
dementia were excluded as they present infrequently
[22] and typically present with exaggerated functional
deficits and different MCI syndromes [23–25].
The MCI and dementia groups underwent the same
comprehensive review at baseline including neuro-
psychological assessment and Magnetic Resonance Im-
aging or Computerized Tomogram. The purpose and
procedure of the research were explained in advance
and all participants signed an informed consent before
participation in the study. The Medical Ethical Commit-
tee of the University Medical Center Groningen evalu-
ated the study and judged that it did not need ethical
approval under Dutch law.
A power calculation was performed a priori, to estab-
lish the sample size, using the WINPEPI software
programme PAIRSetc [26, 27]. Based upon the original
validation results of the Qmci compared to the SMMSE
[15], it was expected that the accuracy, as indicated by
the area under the curve (AUC) of receiver operating
characteristic (ROC) curves, of the Qmci would be
85 % compared to approximately 65 % for the SMMSE,
to differentiate MCI from NC. To detect a 20 %
(medium to large effect size) difference in sensitivity
and specificity, between the two tests, at a significance
level of 0.05 and power of 80 %, 76-paired observations
were required. The sample size needed to distinguish
MCI from dementia was not estimated as a significant
difference between the Qmci and the SMMSE would
not be expected [15].
Data collection
Demographic data (age and gender) were collected dur-
ing each visit to the geriatric department. Patients were
classified by a consultant geriatrician and divided into
three groups (NC, MCI or dementia). A trained rater ad-
ministered both the Qmci-D (score range 0–100, im-
paired to normal) and SMMSE-D (score range 0–30,
impaired to normal) on the same day, in a counterba-
lanced fashion, blind to the final diagnosis.
Statistical analysis
Data were analyzed using SPSS version 20.0 and the stat-
istical programming language R. The Shapiro-Wilk test
was used to test for normality. Differences in Qmci-D
and SMMSE-D scores, between groups, were tested by
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one-way analysis of variance (ANOVA). Analysis of co-
variance (ANCOVA) was used to test differences be-
tween participant groups, controlling for participant
characteristics such as age. Post hoc pair-wise compari-
sons were performed using the Tukey’s honest signifi-
cant difference (HSD) test. A p-value < 0.05 was
regarded as significant. Bootstrapped ROC curves were
generated [28] to analyze the discriminatory characteris-
tics of the Qmci-D and SMMSE-D [29]. Differences be-
tween AUCs were calculated using the DeLong
approach [30].
Results
In total, 90 participants, 41 males (46 %) and 49 females
(54 %), were included in this study. In this sample, 35
(39 %) had NC, 30 (33 %) had MCI and 25 (28 %) were
diagnosed with dementia. The overall mean age of the
sample was 72.9, standard deviation (SD) of 9.1 years.
The NC group (mean age 68.7) was younger than the
MCI (mean age 79.1) and dementia (mean age 79.2)
groups (p < 0.001). The NC group had a mean Qmci-D
score of 64 (SD 10.5) and a mean SMMSE-D score of 28
(SD 1.8). The mean Qmci-D score for the MCI group
was 46 (SD 11.8) compared with 24 (SD 2.9) for the
SMMSE-D, while the dementia group scored 34 (SD
15.8) for the Qmci-D and 22 (SD 4.4) for the SMMSE-D.
These scores and demographic data are summarized in
Table 1.
One-way ANCOVA, used to test for differences in
SMMSE-D scores between the three groups (NC,
MCI and dementia), showed that the mean scores dif-
fered significantly across the three groups (F = 20.55,
df = 3,86, p < 0.001). Post hoc pair-wise comparisons
using the Tukey’s HSD test showed significant mean
differences between groups (p < 0.05). The mean
scores for the Qmci-D also differed significantly between
the three groups; (F = 33.24, df = 3,86, p < 0.001). The dif-
ferences between groups are presented as boxplots in
Fig. 1. ANOVA post-hoc testing for multiple comparisons,
showed a significant difference in mean scores between
the dementia and NC groups, for both tests (see Table 2).
Comparisons of the AUC of ROC curves and the
point estimates (cut-off scores), providing the optimal
sensitivity and specificity, are presented in Fig. 2.
These show that the Qmci-D was more accurate than
the SMMSE-D in discriminating between dementia
and NC, with an AUC of 0.95 (95 % CI 0.90–0.99),
compared to 0.89 (95 % CI 0.80–0.96) for the
SMMSE-D (see Fig. 2a, b). The difference was signifi-
cant (p = 0.006). Both the Qmci-D and the SMMSE-D
discriminated MCI from NC, with ANOVA post-hoc
tests showing a significant mean difference between
the MCI and NC groups (p < 0.001). The AUC of the
Qmci-D, in discriminating MCI from NC, was mar-
ginally greater at 0.86 (95 % CI 0.77–0.95), compared to
0.84 (95 % CI 0.74–0.94) for the SMMSE-D (see Fig. 2c,
d). This difference was non-significant (p = 0.335). At the
point estimate the Qmci-D had a sensitivity of 70 % and
specificity of 94 % compared to a sensitivity of only 60 %
and a similar specificity of 94 % for the SMMSE-D. As for
the discrimination of MCI from dementia, ANOVA post-
hoc tests, showed a significant mean difference (p < 0.001)
between these participants with the Qmci-D. The differ-
ence between scores for the MCI and dementia groups,
for the SMMSE-D (p = 1.02) was not significant. The score
test for homogeneity of variances across groups in
ANCOVA indicated that homogeneity for the Qmci is
rejected. Heteroscedasticity-corrected SEs and Tests after
ANCOVA [31] indicated that the difference in Qmci-D
mean scores after correction for age, between MCI and
Table 1 Characteristics of patients with mild cognitive impairment (MCI), dementia, and participants with normal cognition (NC)
including their Quick Mild Cognitive Impairment (Qmci-D) screen and Standardised Mini-Mental State Examination (SMMSE-D) scores
Group Dementia MCI Normal cognition
Number of participants 25 30 35
Age
Mean (SD) 79.2 (5.7) 79.1 (5.9) 68.7 (9.0)
Median (IQR) 80 (84–76 = 8) 80 (83–74 = 9) 68 (77–61 = 16)
Gender
(% female) 48 % 56 % 57 %
Qmci-D (range 0–100)
Mean Score (SD) 34 (15.8) 46 (11.8) 64 (10.5)
Median Score (IQR) 35.5 (48–21 = 17) 46.8 (54–38 = 16) 64.5 (72–55 = 17)
SMMSE-D (range 0–30)
Mean Score (SD) 22 (4.4) 24 (2.9) 28 (1.8)
Median Score (IQR) 23 (26–18 = 8) 23.5 (26–22 = 4) 28 (29–27 = 2)
SD Standard Deviation, IQR inter-quartile range, IQR Q1-Q3, Q1 1st Quartile, Q3 3rd quartile
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NC as well as between MCI and dementia, were signifi-
cantly different from zero. The ability of the Qmci-D, to
discriminate MCI from dementia, was significantly greater
(p = 0.024) than the SMMSE-D, AUC of 0.73 (95 % CI
0.59–0.85) compared to 0.60 (95 % CI 0.45–0.75), respect-
ively (See Fig. 2e, f ). At the point estimate the Qmci-D
had a modest sensitivity of 64 % to differentiate MCI from
dementia, although this compared favorably to the
SMMSE-D with a sensitivity of only 28 %.
When moderate and severe dementia cases were re-
moved from analysis, the AUC of the Qmci-D and
SMMSE-D for differentiating MCI from mild dementia
cases alone was unchanged at 0.62 and 0.54, p = 0.03,
respectively.
Discussion
The goals of this study were to adapt the Qmci for use
in Dutch-language countries and to explore its concur-
rent validity against the most commonly used short cog-
nitive screen in Dutch, the SMMSE-D. The results show
that the Qmci-D is more accurate than the SMMSE-D
in differentiating dementia from NC. It had only fair ac-
curacy (AUC 0.73) at differentiating MCI from demen-
tia, although it was significantly more accurate than the
SMMSE (AUC 0.60). In this study however, the
SMMSE-D wasn’t able to discriminate MCI from de-
mentia with a very poor sensitivity of 24 %, particularly
when moderate to severe cases were excluded. Based
upon this data it would appear that both instruments
have limited ability to separate MCI from dementia. This
is markedly different from the initial validation of the
English language version of the Qmci against the
SMMSE [15], which in a much larger sample of almost
1000 Canadians, suggested that both had excellent ac-
curacy (AUC >0.90), although it showed no significant
difference between the two instruments in their ability
to distinguish MCI from dementia. There was also no
significant difference between the tests’ ability to dis-
criminate between MCI and NC in this sample, although
the accuracy of both tests was good, suggesting that
both were able to separate MCI from NC. This again dif-
fers from the initial validation, where the Qmci showed
Fig. 1 Boxplots representing scores on the (a) Qmci-D (score range 0–100) and (b) SMMSE-D (score range 0–30) in dementia, MCI and normal
cognition groups
Table 2 ANOVA Post-Hoc tests: multiple comparisons between NC, MCI and Dementia groups
Dependent
Variable
Group Group Mean
Difference
Std.
Error
P-value 95 % Confidence Interval
Lower Bound Upper Bound
Qmci-D MCI Dementia 12.56 3.40 0.001 4.25 20.87
NC MCI 17.19 3.13 <0.001 9.55 24.82
NC Dementia 29.75 3.29 <0.001 21.71 37.78
SMMSE-D MCI Dementia 1.79 0.83 0.102 −0.24 3.83
NC MCI 3.70* 0.77 <0.001 1.84 5.58
NC Dementia 5.50* 0.81 <0.001 3.54 7.47
SMMSE-D Dutch version of the Standardised Mini Mental State Examination, Qmci-D Dutch version of the Quick Mild Cognitive Impairment Screen, MCI Mild
Cognitive Impairment, NC Normal Cognition
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significantly greater accuracy over the SMMSE. This dis-
crepancy may relate to the small sample size, suggesting
that this study was underpowered to show superiority of
one instrument over the other. This said, the goal of this
study was not to show superiority of a Dutch language
version of the Qmci, the Qmci-D, rather it was to show
the concurrent validity of the translation against a widely
used screening instrument.
Fig. 2 Bootstrapped ROC curves with 95 % confidence intervals demonstrating sensitivities and specificities of (a) Qmci-D and (b) SMMSE-D in
differentiating dementia from normal cognition, the (c) Qmci-D and (d) SMMSE-D in differentiating MCI from normal cognition, and the
(e) Qmci-D and (f) SMMSE-D in differentiating MCI from dementia
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The strength of this study is the robust analysis with
bootstrapped ROC curves and 95 % confidence intervals,
to identify the discriminatory characteristics of both
screening tools. This method provides more accurate re-
sults than non-bootstrapped methods, especially when
analyzing smaller sample sizes. The 95 % confidence in-
tervals obtained from the bootstrap and the asymptotic
approach [30], were in all cases virtually equal. This in-
dicates that the intervals are valid.
The study has limitations. First, the diagnosis of
MCI was based on clinical criteria, which may have
increased the heterogeneity of this group and led to
some bias. However, no single gold standard criterion
for MCI exists and there is still a lack of uniformity
in the clinical diagnosis of MCI between studies [32].
This said, in this study an objective history of cogni-
tive decline over time was obtained from each pa-
tient’s collateral (family member or caregiver) and
assessed by neuropsychological testing, independent
of the results of the short cognitive screens, in keep-
ing with the National Institute on Aging Alzheimer’s
Association diagnostic guidelines [21]. Second, the
NC group consisted of participants recruited by con-
venience sampling from healthy relatives or caregivers
attending with patients. These participants were sig-
nificantly younger than patients with MCI or demen-
tia. This could have increased heterogeneity and
created bias, explaining why there was no significant
difference in the ability of both instruments to distin-
guish MCI from NC, unlike that seen in the initial
validation of the Qmci [15]. Patients with MCI and
dementia were, however, well matched for age and
gender. ANCOVA testing and post-hoc analysis con-
firmed that differences in mean test score were not
attributable to age. Furthermore, the educational sta-
tus of patients was not recorded routinely, which may
also have created some bias. Third, the sample size
was small and did not exceed the desired 76-paired
observations, calculated as the sample size to detect
differences in accuracy between participants with MCI
and NC for the screening tools. Fourth, the study ex-
cluded those with active depression and less prevalent
dementia subtypes as described above. Active depres-
sion was excluded as these patients may have slower
reaction times and processing speeds [33]. Frontotem-
poral, Parkinson’s disease and Lewy body dementia
often present with exaggerated functional deficits po-
tentially clouding the diagnosis of MCI, the focus of
this study. This may have caused the sample to be
less representative and created some spectrum bias,
limiting the generalizability of the results. Finally, the
study compared the Qmci-D only with the SMMSE-
D. This was because the SMMSE is the most widely
used short cognitive screen [34] and in the initial
validation of the English language version of the
Qmci the comparator was the SMMSE, allowing dir-
ect comparison with the results of that study [15].
The authors acknowledge the importance of future
validation against other short, albeit longer, screens
including the Dutch version of the Montreal cognitive
assessment (MoCA) [35, 36], the Addenbrooke’s Cognitive
Examination-Revised [37] and shorter instruments like
the Mini-Addenbrooke’s Cognitive Examination (M-ACE)
[38]. The authors also caution that screening for cognitive
impairment continues to have challenges and in clinical
practice [39] it remains only one part of a comprehensive
assessment of cognition, and should not be relied upon
exclusively.
Conclusion
In conclusion, this study shows the concurrent valid-
ity of the Qmci-D against the SMMSE-D. The data
suggests that the Qmci-D, although statistically sig-
nificantly more accurate than the SMMSE-D, is lim-
ited in its ability to differentiate MCI from dementia.
The results also suggest that the accuracy of both in-
struments at distinguishing MCI from NC was good
although the Qmci was more accurate than the
SMMSE in separating dementia from NC in a Dutch
speaking population. Given this, albeit limited analysis
in a small sample, as well as its brevity and ease of
administration [15–17, 40], the Dutch version of the
Qmci, the Qmci-D, appears useful as a short cognitive
screen. Further research is now required to confirm
these findings with a larger sample including other
dementia subtypes and to compare the test to other
cognitive screens including the MoCA and M-ACE.
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